Showing results (921-930 of 1,095) with videos related to
Sort By:
Pageof 110
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2014
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patientsCesare Gridelli, Silvia Novello, Nicoletta Zilembo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2023
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 StudySilvia Novello, Dariusz M Kowalski, Alexander Luft, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso TrialFederica Grosso, Nicola Steele, Silvia Novello, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 9, 2016
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment RegimensLuis Paz-Ares, Vera Hirsh, Li Zhang, et al.European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARDZofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.JAMA Network Open|October 14, 2021
Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients With Cancer: The HuCare2 Stepped-Wedge Cluster Randomized TrialCaterina Caminiti, Maria Antonietta Annunziata, Claudio Verusio, et al.JTO Clinical and Research Reports|September 30, 2021
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042Aaron S Mansfield, Roy S Herbst, Gilberto de Castro, et al.Function (Oxford, England)|March 25, 2022
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical PerformanceAlba Clara Sarti, Valentina Vultaggio-Poma, Simonetta Falzoni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2019
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung CancerJulien Mazieres, Dariusz Kowalski, Alexander Luft, et al.ESMO Open|November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50A De Giglio, L Zullo, A Di Federico, et al.Pageof 110